Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©)
The purpose of the assessment is to evaluate Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Final version of the assessment was published in October 2017. Below is the documentation provided by the Joint Assessment authoring team:
Regorafenib_Final Assessment Report
External comments & answers 2nd draft assessment regorafenib_1
Project Plan PTJA02 Regorafenib for HCC (FINAL)_0_1